Er Therapeutics Financials
| PNGM Stock | USD 0.0001 0.00 0.00% |
The essential information of the day-to-day investment outlook for Er Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Er Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Er Therapeutics.
Net Income |
|
PNGM | Select Account or Indicator |
Er Therapeutics Stock Summary
Er Therapeutics competes with Atlas Corp, PureCycle Technologies, and GCM Grosvenor. Pengram Corporation, an exploration stage mining company, engages in the acquisition, exploration, and development of natural resource properties, primarily gold. Pengram Corporation was founded in 2006 and is based in Bellingham, Washington. Pengram Corp operates under Other Industrial Metals Mining classification in the United States and is traded on OTC Exchange.Specialization | Basic Materials, Other Industrial Metals & Mining |
| Instrument | USA Stock View All |
| Exchange | OTCCE Exchange |
| ISIN | US7070622045 |
| Business Address | 1200 Dupont Street, |
| Sector | Metals & Mining |
| Industry | Materials |
| Benchmark | Dow Jones Industrial |
| Website | pengramgold.com |
| Phone | 360 255 3436 |
| Currency | USD - US Dollar |
Er Therapeutics Key Financial Ratios
| Net Income | (426.95 K) | |||
| Total Asset | 423.6 K |
PNGM Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Er Therapeutics's current stock value. Our valuation model uses many indicators to compare Er Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Er Therapeutics competition to find correlations between indicators driving Er Therapeutics's intrinsic value. More Info.Er Therapeutics is considered to be number one stock in return on asset category among its peers. It also is rated top company in current valuation category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Er Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Er Therapeutics Systematic Risk
Er Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Er Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was twenty-eight with a total number of output elements of thirty-three. The Beta measures systematic risk based on how returns on Er Therapeutics correlated with the market. If Beta is less than 0 Er Therapeutics generally moves in the opposite direction as compared to the market. If Er Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Er Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Er Therapeutics is generally in the same direction as the market. If Beta > 1 Er Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Er Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in PNGM Stock, please use our How to Invest in Er Therapeutics guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Diversified Metals & Mining space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Er Therapeutics. If investors know PNGM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Er Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (0.95) |
The market value of Er Therapeutics is measured differently than its book value, which is the value of PNGM that is recorded on the company's balance sheet. Investors also form their own opinion of Er Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Er Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Er Therapeutics' market value can be influenced by many factors that don't directly affect Er Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Er Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Er Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Er Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.